 Sesen Bio Inc NASDAQ: SESN has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive bladder cancer NMIBC following its Clinical Type A meeting with the FDA. Following the meeting, the Company has agreed to conduct a randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators choice of intravesical chemotherapy. 